A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunologic Effects of BMS-986256, and a Relative Bioavailability Study in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs BMS-986256 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 25 Nov 2019 Status changed from active, no longer recruiting to completed.
- 23 Sep 2019 Planned End Date changed from 25 Jul 2019 to 7 Oct 2019.
- 23 Sep 2019 Planned primary completion date changed from 25 Jul 2019 to 7 Oct 2019.